Pfizer Medical Information

Prevnar 13® Educational Videos

Invasive pneumococcal disease and Prevnar 13®.

Invasive pneumococcal disease is still out there and still a threat to children less than 5 years of age.1 These videos provide expert opinions on invasive pneumococcal disease and the need to be diligent in immunizing children against this vaccine-preventable disease.


CDC Announcement via MMWR Publication

This video discusses the recent announcement by the CDC via the November 4th MMWR publication entitled “Invasive Pneumococcal  Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged ≤59 Months—Selected U.S. Regions, 2010–2011” reminding physicians to vaccinate age appropriate children against invasive pneumococcal disease (IPD). Watch this video to learn about the importance of helping to protect children 15 months to 5 years of age fully immunized with 4 doses of Prevnar® against 6 additional serotypes of IPD with Prevnar 13®.

The Risk of Vaccine-Preventable Diseases in the Child Care Setting

Studies show that 55% of children less than 5 years of age attend day care. This video discusses the increased risk of vaccine-preventable diseases, including invasive pneumococcal disease (IPD), associated with day care attendance. Watch this video to learn about the particular risks of vaccine-preventable diseases for children in day care, and how vaccination with Prevnar 13® protects against 13 serotypes of IPD, including 19A.

Overcoming Common Barriers to Vaccination in Children Under 5 Years of Age

This video addresses common barriers to vaccinating children under 5 years of age who are enrolled in day care against invasive pneumococcal disease (IPD). It also discusses vaccination adherence and outlines ways that health care professionals can help ensure that children receive the vaccinations recommended by the CDC. Thirty-six states and D.C. have PCV child care entry requirements, and it’s important that pediatricians ensure that their patients are properly vaccinated with Prevnar 13® prior to entry in day care to help reduce the risk of IPD caused by the serotypes included in the vaccine.

The immune response induced by the above Prevnar 13® schedule may result in lower antibody concentrations
for the 6 additional serotypes (types 1, 3, 5, 6A, 7F, and 19A), compared to antibody concentrations following
4 doses of Prevnar 13®.2

INDICATIONS

  • Prevnar 13® is a vaccine indicated for active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
  • In children 6 weeks through 5 years for invasive pneumococcal disease and otitis media (caused by 7 of the 13 serotypes only [4, 6B, 9V, 14, 18C, 19F, and 23F])
  • In adults 50 years of age and older for pneumococcal pneumonia and invasive disease. Indication is based on immune responses

Limitations of Use and Effectiveness

  • Prevnar 13® will only help protect against S pneumoniae serotypes in the vaccine
  • Effectiveness when administered <5 years after pneumococcal polysaccharide vaccine is not known

IMPORTANT SAFETY INFORMATION

  • Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
  • Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status and the potential benefits and risks
  • In infants and toddlers, the most commonly reported serious adverse events were bronchiolitis (0.9%), gastroenteritis (0.9%), and pneumonia (0.9%)
  • In infants and toddlers, the most commonly reported solicited adverse reactions were injection site tenderness, redness, or swelling, irritability, decreased appetite, decreased or increased sleep, and fever
  • In adults, antibody responses to Prevnar 13® were diminished when given with inactivated Influenza Virus Vaccine
  • In adults, the commonly reported solicited adverse reactions were pain, redness and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle or joint pain, decreased appetite, chills, or rash

Please see full Prescribing Information for Prevnar 13®

References

  1. Centers for Disease Control and Prevention. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine — United States, 2007. MMWR. 2010;59:253-257
  2. Prevnar 13® [Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)] Prescribing Information, Wyeth Pharmaceuticals Inc.
These documents are in PDF (portable document format).
PDF files require Adobe Reader; click here to download this free program.

PREVNAR and PREVNAR 13 are registered trademarks of Wyeth LLC.